Drug Profile
Obecabtagene autoleucel - Autolus
Alternative Names: Anti-CD19 CAR T cell therapy - Autolus; AUTO 1; CAT19; CD19 CAR T-cells - Autolus; CD19CAT-41BBZ CAR T-cells - Autolus; Obe-celLatest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator University College London
- Developer Autolus; University College London
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I Lymphoma
- No development reported Burkitt's lymphoma
Most Recent Events
- 09 Dec 2023 Efficacy and adverse events data from the phase I/II ALLCAR19 trial and phase Ib/II FELIX trial in Precursor cell lymphoblastic leukaemia-lymphoma, Non-Hodgkin's Lymphoma and Chronic lymphocytic leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Efficacy and safety data from a phase I/II FELIX trial in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Burkitt's-lymphoma(In adolescents, In children, In infants, Recurrent, Second-line therapy or greater, In adults) in United Kingdom (IV, Injection)